Other
BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License
Internal License Transfer Closes as BriaCell Consolidates Pipeline Amid Cash Burn and Dilution Overhang
Executive Summary
- BriaCell Therapeutics and its majority-owned subsidiary BriaPro completed an asset purchase transaction transferring BriaCell's exclusive worldwide license to develop and commercialize soluble CD80 (sCD80) to BriaPro.
- As consideration, BriaPro issued 23,972,589 common shares to BriaCell, valued at approximately $1.18 million, increasing BriaCell's ownership stake in BriaPro from ~66.7% to ~78%.
- BriaCell extended a credit facility of up to $3 million to BriaPro to fund ongoing research and development, with each draw subject to BriaCell's approval.
- BriaPro will pay a 2% royalty to the University of Maryland, Baltimore County (UMBC) on any future commercialization of sCD80 products.
- The transaction received 99.81% approval from disinterested BriaPro shareholders and was supported by an independent fairness opinion.
- Jamieson Bondarenko was appointed Chairman of the BriaPro board following the closing.
Material Impact
- The news represents the closing of an internal corporate restructuring that was previously announced on February 18, 2026. It does not introduce new clinical data, external partnerships, or incremental capital.
- The $1.18 million share consideration and $3 million internal credit facility are accounting and operational housekeeping measures that do not alter the company's consolidated cash position or clinical trajectory.
- The transaction is fully expected, aligns with prior disclosures, and carries no surprise elements. It is classified as routine corporate administration.
- No material impact on near-term valuation, cash runway, or Phase 3 trial timelines.
BCT · Price
Company Overview
- BriaCell Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies for metastatic breast cancer (MBC) and other solid tumors.
- Flagship project: Bria-IMT (SV-BR-1-GM), an allogeneic whole-cell cancer vaccine, currently in a pivotal Phase 3 trial (BRIA-ABC) combined with an immune checkpoint inhibitor. The trial targets overall survival as its primary endpoint and holds FDA Fast Track designation.
- Secondary pipeline: Bria-OTS+, a next-generation off-the-shelf personalized immunotherapy platform with candidates for breast (Bria-BRES+) and prostate (Bria-PROS+) cancer, supported by a $2 million NCI SBIR award.
- The company recently consolidated its sCD80 asset into its BriaPro subsidiary to streamline development and potential future financing or spin-out options.
More from BRIACELL THERAPEUTICS CORP. J
Jun 25, 2026 · 07:30